Vident Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vident Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$377K	Buy	6,584 +78	+1%	+$4.27K	﹤0.01%	1506
2026 Q1	$368K	Buy	6,506 +1,647	+34%	+$96K	﹤0.01%	1401
2025 Q4	$289K	Sell	4,859 -3,844	-44%	-$209K	﹤0.01%	1390
2025 Q3	$471K	Sell	8,703 -180	-2%	-$10.3K	﹤0.01%	1228
2025 Q2	$488K	Buy	8,883 +2,837	+47%	+$167K	0.01%	1067
2025 Q1	$427K	Buy	+6,046	New	+$407K	0.01%	1118
2024 Q3	–	Sell	-2,877	Closed	-$237K	–	1434
2024 Q2	$237K	Buy	2,877 +160	+6%	+$13.3K	0.01%	1214
2024 Q1	$237K	Buy	2,717 +14	+0.5%	+$1.25K	﹤0.01%	1136
2023 Q4	$261K	Buy	2,703 +231	+9%	+$20.4K	0.01%	1066
2023 Q3	$219K	Buy	+2,472	New	+$220K	0.01%	1064

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vident Advisory's BMRN Position: Q2 2026 in Review

Vident Advisory increased its BioMarin Pharmaceuticals (BMRN) stake by 1.2% in Q2 2026, buying an estimated $4.27K and bringing the position to 6,584 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Vident Advisory first reported a position in BMRN in Q3 2023 and has held it in 10 quarters since. The position peaked at $488K in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Vident Advisory held 6,584 shares of BioMarin Pharmaceuticals worth $377K as of Q2 2026.
Vident Advisory bought 78 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.27K.
BioMarin Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1506 holding.
Vident Advisory first reported a position in BioMarin Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
Vident Advisory's BioMarin Pharmaceuticals position peaked at $488K in Q2 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.